Bioventus BVS U.S. Segment — Total Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bioventus's u.s. segment — total net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bioventus's U.S. segment — total net sales?
- Bioventus (BVS) reported U.S. segment — total net sales of $116.45M in Q1 2026.
- How has Bioventus's U.S. segment — total net sales changed year-over-year?
- Bioventus's U.S. segment — total net sales increased by 5.4% year-over-year, from $110.52M to $116.45M.
- What is the long-term trend for Bioventus's U.S. segment — total net sales?
- Over 3 years (2022 to 2025), Bioventus's U.S. segment — total net sales has grown at a 3.3% compound annual growth rate (CAGR), from $455.25M to $502.1M.
- What does U.S. segment — total net sales mean?
- This metric represents the total revenue generated from the sale of medical technology products and services within the United States market. It serves as a primary indicator of the company's commercial reach and market penetration in its largest geographic region.